Search
cytarabine/daunorubicin; CPX-351 (Vyxeos)
Indications:
- treatment-related acute myeloid leukemia
- myelodysplasia-related acute myeloid leukemia
Adverse effects:
- hemorrhage
- febrile neutropenia, bacteremia, chills
- rash, edema, mucositis
- nausea, vomiting, diarrhea, constipation
- musculoskeletal pain, abdominal pain, headache
- cough, dyspnea, pneumonia
- fatigue, decreased appetite, sleep disorders
- arrhythmias
Notes:
- CPX-351 (Vyxeos) is a liposomal formulation of cytarabine & daunorubicin
General
antineoplastic combination (combination chemotherapy)
References
- Bankhead C.
FDA Approves Fixed Chemo Combo for AML Subtypes.
First approval for treatment- and myelodysplasia-related AML.
MedPage Today. August 03, 2017
https://www.medpagetoday.com/HematologyOncology/Leukemia/67045
Components
cytosine arabinoside; cytarabine (Cytosar, ARA-C, HiDAC, Depocyt)
daunorubicin, daunomycin; DNR (Cerubidine, DaunoXome)